Kivorent News

Wednesday, November 18, 2026

Health techNews

iCOR Medical wins FDA clearance for a disposable 30-day ECG monitor

iCOR Medical says the FDA cleared iCOR Beat, a one-ounce, prescription-only heart rhythm monitor worn for up to 30 days that patients keep afterward. The Florida company plans to sell it through wearable and telehealth partners.

Pulse, covering wearables and health sensors
, 3 min read

30 daysLongest continuous recording, LTR model

What to know

  • iCOR Medical says the FDA cleared iCOR Beat under 510(k) K260383; it announced the clearance on November 16, 2026.
  • The single-lead ECG monitor records continuously for up to 14 days (STR model) or 30 days (LTR model) and needs no charging.
  • It is prescription-only, and cardiologists read the recordings, according to the company.

iCOR Medical, a heart-monitoring startup in Coral Springs, Florida, says the US Food and Drug Administration has cleared its iCOR Beat ambulatory electrocardiogram (ECG) monitor. The company announced the 510(k) clearance, number K260383, on November 16, 2026. Healthcare IT Today listed it in its roundup of news from the HLTH conference the next day. The figures below come from the company's release and product pages; Kivorent News has not seen the FDA's clearance letter.

What the device is

iCOR Beat is a single-lead ECG recorder that sticks to the chest with standard snap electrodes. It weighs about one ounce (28 grams). The release describes two versions: an STR model that records continuously for up to 14 days and an LTR model that records for up to 30 days. There are no battery changes or charging during the test.

The patient changes the electrodes every 48 hours or after showering. The monitor is rated IP55 against dust and water spray, and the company's site calls it safe for the shower.

Recordings travel over Bluetooth to the BeatSuite Mobile app on the patient's iPhone or Android phone, then to iCOR's BeatSuite platform for the ordering doctor. The device also stores data internally, so a recording can be recovered if the phone connection drops. Cardiologists in all 50 states interpret the results, according to the release.

Who it is for

This is a prescription device, not a consumer gadget. The cleared use covers adults 18 and older with no symptoms, or with passing symptoms such as palpitations, shortness of breath, dizziness, fainting or near-fainting, fatigue, chest pain or anxiety. The release ties the product to atrial fibrillation (AFib), the most common heart rhythm disorder, but does not list which rhythms the monitor's reports flag.

Chief medical officer Lee A. Surkin, a cardiologist, called it "a major advancement in ambulatory cardiac monitoring."

Built to be kept, sold through partners

The difference iCOR is pitching is cost and logistics. Doctors can let patients keep the monitor when the test ends, which the company says removes return shipping and reprocessing.

iCOR also plans a partner-branded program for wearable companies, telemedicine services and membership lab platforms. iCOR would handle inventory, shipping, patient support, reports and cardiologist reads. The company has not named partners, a price, insurance coverage or a launch date.

That pitch lines up with a pattern on this beat. A smartwatch can flag a possible irregular rhythm, as smartwatch ECG features do, but a diagnosis usually needs a longer prescription recording. PulseAI and AliveCor are working on the software side of that handoff (PulseAI's clearance, their KardiaCare partnership). iCOR is betting on cheap hardware for the next step.

What is still unclear

The release does not describe any automated analysis. The company's homepage says that "in MCT mode" its algorithms detect arrhythmias in real time, but the release does not mention that mode. A 510(k) clearance means the FDA found the device substantially equivalent to one already on the market. It is not an approval and not proof that the device beats other monitors. Our explainer on clearance versus approval and our guide to reading a 510(k) summary cover the difference.

Why it matters

Long-term heart rhythm monitoring is how doctors catch intermittent AFib that a watch alert or a short office ECG can miss. A disposable 30-day recorder sold through wearable and telehealth companies could make that test easier to order from home, if price and insurance coverage follow.

This article is general information about how technology works. It is not medical advice. Talk to a clinician about your own health.

Sources

Heart health techFDA and health regulationWearablesDigital health and AI in care

Written by an AI correspondent under standards set by editor Jacob Knight. Spotted an error? Tell us and we will fix it.